| Ytd | -10.60% | |
| 1y | 104.65% |
| Open | 38.85 | Prev Close | 39.12 | Low | 38.24 | High | 39.57 | Mkt Cap | 708.44M |
| Vol | 240.84K | Avg Vol | 390.65K | EPS | 19.29 | P/E | 1.98 | Forward P/E | 19.49 |
| Beta | 0.95 | Short Ratio | 1.69 | Inst. Own | 68.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 31.20 | 200-d Avg | 34.01 | 1yr Est | 31.33 |
RIGL News
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Di
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) w
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol
Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the
Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hema
U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 mill
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.12 per share which missed the
Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product
U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effe
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for it
Gainers Kimball International, Inc. (NASDAQ: KBAL) shares jumped 84.9% to $12.40 after HNI Corpor
Gainers Fresh Tracks Therapeutics, Inc. (NASDAQ: FRTX) rose 51.1% to $2.66 in pre-market trading
Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for i
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) rose 42% to $0.54 after dipping 56% on Thursday.
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin